Opioid Use Disorder Market

Opioid Use Disorder Market by Drug (Buprenorphine [Bunavail, Sublocade, Suboxone, Zubsolv, and Others], Methadone, and Naltrexone), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-844
  • Author: Growth Market Reports
  • Rating: 4.8
  • Total Reviews: 2
  • No. Of Pages: 185
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global opioid use disorder market size is projected to expand at a significant CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the rise in the opioid epidemic in the United States, as well as the implementation of government measures to combat the epidemic.
 

Opioid Use Disorder Market Key Takeaways


Opioids are chemicals that interact with opioid receptors on nerve cells in the body and brain to manage pain. They can be natural, or synthetic produced in laboratories to replicate the qualities of natural opioids. Prescription pain relievers, synthetic opioids, and heroin all fall within this category. Acute pain such as after an injury or surgery, chronic pain, active-phase cancer therapy, palliative care, and end-of-life care are all conditions for which prescription opioids are recommended. Many patients rely on prescription opioids to help them manage their symptoms while under the supervision of a doctor.

Opioids offer a lot of positive reinforcement, which makes it more likely that people will keep taking them despite the bad repercussions. Opioid use disorder is a chronic, life-long disease with devastating implications such as impairment, relapse, and death. In many ways, opioid use disorder is similar to other drug use disorders, but it has a few distinguishing characteristics. Opioids can cause physical dependency in as little as four to eight weeks. Stopping opioid usage abruptly causes significant symptoms in chronic users, such as generalized pain, chills, cramps, diarrhea, dilated pupils, restlessness, anxiety, nausea, vomiting, sleeplessness, and extreme cravings. Because these sensations are so intense, it is easy to feel compelled to keep using opioids to avoid withdrawal. Although there are effective therapies available, only around one out of every four patients with opioid use disorder receives specialized therapy. Individuals with an opioid use problem might benefit from medication-assisted treatment (MAT). It includes a combination of medicine, therapy, and behavioral therapy. Brain chemistry may have a role in both the cause and treatment of mental illness. As a result, drugs may be provided to aid in the modification of one's brain chemistry. Medications are also used to treat opioid cravings, withdrawal symptoms, and to inhibit the euphoric effects of the drugs.

Market Trends, Drivers, Restraints, and Opportunities

  • Increasing consumption of opioid due to increasing prevalence of chronic diseases such as cancer, cardiovascular, pain arising from injuries, and other conditions are expected to propel the market growth during the forecast period.
  • Increasing initiatives by government and private institutes for curbing the increased consumption of opioids are anticipated to fuel the market growth in the coming years.
  • Adverse side effects associated from the administration of drugs for the treatment of opioid addiction is projected to hamper the market growth during the forecast period.
  • Lack of awareness and limited product availability presents as key challenges that can hinder the market expansion during the period.
  • Increased R&D activities and upcoming product launches are projected to offer lucrative opportunities for the market players.

Scope of the Report

The report on the global opioid use disorder market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Opioid Use Disorder Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Drug (Buprenorphine [Bunavail, Sublocade, Suboxone, Zubsolv, and Others], Methadone, and Naltrexone)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Indivior; Alkermes; Titan Pharmaceuticals; Hikma Pharmaceuticals; Teva Pharmaceuticals; MediciNova; Orexo; Camurus; and Omeros.

 

Market Segment Insights

Buprenorphine segment is expected to account for a key share of the market
Based on drug, the opioid use disorder market is segmented into buprenorphine, methadone, and naltrexone. The buprenorphine segment is further sub segmented into bunavail, sublocade, suboxone, zubsolv, and others. The buprenorphine segment is expected to account for a key share of the market during the forecast period owing to increasing usage of buprenorphine-containing products such as bunavail, sublocade, suboxone, and zubsolv. Suboxone is the most commonly prescribed medicine for the treatment of opioid use disorder, owing to its great effectiveness, few side effects, and advantageous formulary coverage.

On the other hand, the sublocade sub segment is anticipated to expand at a rapid pace during the forecast period. Buprenorphine and the Atrigel delivery system are combined in a pre-filled syringe in drug-device combination therapy. Sublocade overcomes the constraints of existing therapies by substituting an injection for daily oral drugs, making diversion and abuse more difficult while also enhancing quality of life.
 

Opioid Use Disorder Market By Drug


North America is anticipated to dominate the market
On the basis of regions, the opioid use disorder market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market during the forecast period. The regional market growth can be attributed to presence of key player, favorable initiatives by governments and wide range of product offering by key players. Several initiatives are being implemented by governments to combat the situation. For example, in January 2018, the United States government started a public awareness campaign to tackle opioid addiction.

On the other hand, Asia Pacific is expected to exhibit a rapid growth rate in the coming years due to increased acceptance of new products and an increase in the prevalence of opioid use disorder. Furthermore, growing patient population and increasing healthcare expenditure in this region are projected to drive the market growth of this region.
 

Opioid Use Disorder Market By Regions

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Opioid Use Disorder Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Opioid Use Disorder Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Opioid Use Disorder Market - Supply Chain
  4.5. Global Opioid Use Disorder Market Forecast
     4.5.1. Opioid Use Disorder Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Opioid Use Disorder Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Opioid Use Disorder Market Absolute $ Opportunity
5. Global Opioid Use Disorder Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Opioid Use Disorder Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Opioid Use Disorder Demand Share Forecast, 2019-2026
6. North America Opioid Use Disorder Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Opioid Use Disorder Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Opioid Use Disorder Demand Share Forecast, 2019-2026
7. Latin America Opioid Use Disorder Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Opioid Use Disorder Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Opioid Use Disorder Demand Share Forecast, 2019-2026
8. Europe Opioid Use Disorder Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Opioid Use Disorder Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Opioid Use Disorder Demand Share Forecast, 2019-2026
9. Asia Pacific Opioid Use Disorder Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Opioid Use Disorder Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Opioid Use Disorder Demand Share Forecast, 2019-2026
10. Middle East & Africa Opioid Use Disorder Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Opioid Use Disorder Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Opioid Use Disorder Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Opioid Use Disorder Market: Market Share Analysis
  11.2. Opioid Use Disorder Distributors and Customers
  11.3. Opioid Use Disorder Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Indivior
     11.4.2. Alkermes
     11.4.3. Titan Pharmaceuticals
     11.4.4. Hikma Pharmaceuticals
     11.4.5. Teva Pharmaceuticals
     11.4.6. MediciNova
     11.4.7. Orexo
     11.4.8. Camurus
     11.4.9. Omeros

Segments Covered in the Report
The global opioid use disorder market has been segmented on the basis of

Drug

  • Buprenorphine
    • Bunavail
    • Sublocade
    • Suboxone
    • Zubsolv
    • Others
  • Methadone
  • Naltrexone

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Indivior
  • Alkermes
  • Titan Pharmaceuticals
  • Hikma Pharmaceuticals
  • Teva Pharmaceuticals
  • MediciNova
  • Orexo
  • Camurus
  • Omeros

 

Key players competing in the opioid use disorder market are Indivior; Alkermes; Titan Pharmaceuticals; Hikma Pharmaceuticals; Teva Pharmaceuticals; MediciNova; Orexo; Camurus; and Omeros.

Some of the key business strategies employed by companies includes mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to increase their market shares. For example, in December 2018 Orexo AB declared that it has acquired the rights to commercialize Zubsolv in all territories outside of the United States from its existing partner Mundipharma.
 

Opioid Use Disorder Market By Key Players

Buy Report